ONCOZEN develops anti-cancer drugs utilizing biotechnology to create dihydroxy phenyl and benzamide compounds with inhibitory activity against cancer and degenerative neurological diseases. The company aims to provide effective treatments for patients facing cancer and rare diseases, addressing the need for novel pharmaceutical solutions in oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers and degenerative neurological diseases lack effective treatments, creating a need for novel pharmaceutical solutions in oncology. Current treatment options may have limited efficacy or significant side effects, highlighting the need for innovative therapies.
Solution
ONCOZEN is a biotechnology company focused on developing first-in-class and best-in-class anti-cancer drugs. The company utilizes biotechnology to create dihydroxy phenyl and benzamide compounds with inhibitory activity against cancer and degenerative neurological diseases. ONCOZEN aims to provide innovative therapies to people facing cancer and rare diseases by responsibly developing and commercializing novel treatments. Their research focuses on identifying and developing differentiated strategies to address unmet needs in oncology.
Target Audience
The primary target audience includes patients facing cancer and rare diseases, as well as healthcare providers seeking novel pharmaceutical solutions in oncology.
Features
- Development of dihydroxy phenyl compounds for cancer treatment.
- Development of benzamide compounds for cancer treatment.
- Focus on first-in-class and best-in-class treatments.
- Research and development of innovative therapies for oncology and rare diseases.